Oppenheimer Maintains Buy Rating on Urogen Pharma with $31 Price Target

Oppenheimer analyst Leland Gershell maintained a Buy rating on Urogen Pharma with a $31 price target, citing the company's strong fundamentals and potential for growth. The analyst consensus on Urogen Pharma is a Strong Buy with an average price target of $33.71, a 77.70% upside from current levels. The company reported a quarterly revenue of $20.25 million and a GAAP net loss of $43.84 million in its latest earnings release.

UroGen Pharma Ltd (URGN) saw its stock price fluctuate between $17.08 and $19.73 on Thursday, August 7, 2025, according to stockinvest.us [1]. The stock experienced a significant decline of -7.10% from $20.01 to $18.59, with analysts suggesting a potential increase in risk over the next couple of days due to the volume increase on falling prices.

Despite the recent volatility, analysts remain optimistic about UroGen Pharma's long-term prospects. Oppenheimer analyst Leland Gershell maintained a Buy rating with a $31 price target, citing the company's strong fundamentals and potential for growth [2]. The analyst consensus on Urogen Pharma is a Strong Buy, with an average price target of $33.71, representing a 77.70% upside from current levels [2].

In its latest earnings release, UroGen Pharma reported a quarterly revenue of $20.25 million and a GAAP net loss of $43.84 million. While the revenue growth indicates a positive trend, the earnings per share figure suggests challenges remain. The company's Jelmyto sales reached $24.2 million, surpassing consensus estimates of $23.1 million by 5% [3].

UroGen Pharma has been focusing on the launch of Zusduri, which received approval in June for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The company views this as a potential $5 billion U.S. market where Zusduri could achieve over $1 billion in peak sales. Guggenheim analysts raised their price target to $32.00 from $30.00, maintaining a Buy rating [3].

Investing.com reported that the company's impressive gross profit margin of nearly 90% and strong recent performance, with a 73% gain over the past six months, suggest potential for significant growth. UroGen began a phased launch with product availability starting July 1 using a miscellaneous J-code, with management expecting an inflection point in the first quarter of 2026 after receiving a permanent J-code [3].

UroGen Pharma's Phase III UTOPIA (EGX:UTOP) trial of UGN-103 has completed enrollment, with top-line results expected by year-end 2025. The company's Phase II UGN-103 trial results showed significant efficacy, with a 94% response rate in the first 3 months [3].

References:
[1] https://stockinvest.us/stock/URGN
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TZ2O3:0-urogen-pharma-ltd-reports-results-for-the-quarter-ended-june-30-earnings-summary/
[3] https://www.investing.com/news/analyst-ratings/guggenheim-raises-urogen-pharma-stock-price-target-to-32-on-zusduri-launch-93CH-4180851